Cargando…
Testing P2Y12 platelet inhibitors generics beyond bioequivalence: a parallel single-blinded randomized trial
Cardiovascular diseases are the leading cause of death worldwide. Ticagrelor is an oral antiplatelet drug used in acute coronary syndrome. Although generic drugs are approved for their bioequivalence to the original product, they are not necessarily to be therapeutically equivalent. This study was c...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382000/ https://www.ncbi.nlm.nih.gov/pubmed/35978315 http://dx.doi.org/10.1186/s12959-022-00405-y |